MyAverix Finance
ST · Healthcare
Infant Bacterial Therapeutics AB (publ) (IBT-B)
Biotechnology
Infant Bacterial Therapeutics AB (publ) (IBT-B) is listed on ST in the Healthcare sector. Industry: Biotechnology. As of 2026-05-24, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.
Key metrics for IBT-B
Infant Bacterial Therapeutics AB (publ) (IBT-B) — FAQ
What is IBT-B's P/E ratio?
The price-to-earnings (P/E) ratio for Infant Bacterial Therapeutics AB (publ) (IBT-B) is 25.00 (data as of 2026-05-24).
Does Infant Bacterial Therapeutics AB (publ) pay a dividend?
Dividend yield is not available in the current snapshot for Infant Bacterial Therapeutics AB (publ) (IBT-B). Check the MyAverix Finance app for the latest dividend data.
What sector is Infant Bacterial Therapeutics AB (publ) in?
Infant Bacterial Therapeutics AB (publ) (IBT-B) is classified in the Healthcare sector (Biotechnology industry).
What exchange is IBT-B listed on?
IBT-B is listed on ST.
Full report in the app
Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.